News coverage about Theravance Biopharma (NASDAQ:TBPH) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Theravance Biopharma earned a coverage optimism score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.0937920279198 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Here are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- Theravance Biopharma (TBPH) Downgraded by ValuEngine (americanbankingnews.com)
- Theravance Biopharma Highlights Landmark IMPACT Study Published in NEJM Showing Significant Benefits of Trelegy Ellipta for COPD Patients (finance.yahoo.com)
- Zacks: Analysts Anticipate Theravance Biopharma (TBPH) Will Post Quarterly Sales of $5.74 Million (americanbankingnews.com)
- Theravance Biopharma to Present New Data from Multiple Studies of VIBATIV® (telavancin) at 2018 ECCMID™ Conference (finance.yahoo.com)
- Theravance Biopharma (TBPH) Expected to Post Earnings of -$1.29 Per Share (americanbankingnews.com)
TBPH has been the subject of several recent research reports. Cantor Fitzgerald set a $55.00 price target on shares of Theravance Biopharma and gave the stock a “buy” rating in a research note on Tuesday, February 27th. ValuEngine raised shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, April 3rd. Leerink Swann boosted their price target on shares of Theravance Biopharma from $45.00 to $48.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Piper Jaffray reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Theravance Biopharma in a research note on Thursday, March 29th. Finally, BidaskClub raised shares of Theravance Biopharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, January 20th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $42.43.
Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($1.64) EPS for the quarter, missing the consensus estimate of ($1.15) by ($0.49). The firm had revenue of $4.52 million for the quarter, compared to the consensus estimate of $3.71 million. Theravance Biopharma had a negative net margin of 1,855.42% and a negative return on equity of 136.86%. equities analysts anticipate that Theravance Biopharma will post -4.61 earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Theravance Biopharma (TBPH) Share Price” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://stocknewstimes.com/2018/04/20/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-theravance-biopharma-tbph-share-price.html.
About Theravance Biopharma
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company offers VIBATIV (telavancin), a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.